AstraZeneca R&D Bangalore

AstraZeneca R&D Bangalore is dedicated to work on the Developing World Diseases Medicine. Currently the focus is on discovering new treatments for tuberculosis (TB) .

The medicines now used to treat TB were developed more than forty years ago. Since that time there has been limited progress in developing new therapies against this increasing global health threat. The lack of new treatments has been compounded by the increasing ability of infectious organisms to evolve, adapt and develop resistance to existing drug therapies.

AstraZeneca scientists in Bangalore, in collaboration with AstraZeneca genomics and infection research centres in Boston, USA, and with external academic leaders in the field, are employing advanced techniques to develop improved diagnostic tests, identify new treatment targets and uncover more effective therapies against the disease that overcome the increasing problem of drug resistance.

AstraZeneca is the only pharmaceutical company in the world with a research programme in India totally dedicated to TB. AstraZeneca investment of US$ 35 millions in next 5 years is a part of its commitment to the development of novel therapies to treat infectious diseases that pose an increased threat to developing nations.